ALTERNATIVE FINANCING FORMS
FOR ENTREPRENEURS AND INVESTORS

News

McDermott advises Paragon portfolio company APONTIS PHARMA AG on IPO

Photo: Simon Weiss, Part­ner at McDer­mott Will & Emery, Frank­furt a.M./Düsseldorf
11. May 2021

Frank­furt a.M. — McDer­mott Will & Emery, as tran­sac­tion coun­sel, advi­ses the issuer APONTIS PHARMA AG, its main share­hol­der, the invest­ment company Para­gon Part­ners, as well as the joint bookrun­ners Hauck & Aufhäu­ser and M.M.Warburg on the IPO at the Frank­furt Stock Exchange.

The place­ment price for the IPO was set at 19.00 euros per share. The place­ment volume totals 101 million euros. A total of 5,290,000 shares were placed with inves­tors as part of the IPO, which also inclu­ded a U.S. tran­che in accordance with Rule 144A of the U.S. Secu­ri­ties Act. The place­ment inclu­des 2,000,000 new shares from a cash capi­tal incre­ase as well as 1,600,000 exis­ting shares in connec­tion with a base deal, 1,000,000 exis­ting shares in connec­tion with a top-up option and 690,000 exis­ting shares in connec­tion with an over-allo­t­­ment option from the holdings of the main share­hol­der Para­gon Part­ners. The first day of trading on the Frank­furt Stock Exchange is sche­du­led for May 11, 2021. The exis­ting share­hol­ders Para­gon Part­ners and the manage­ment of APONTIS PHARMA will remain share­hol­ders in the company after the place­ment with a stake of 31% and 7%, respectively.

APONTIS PHARMA AG is a leading phar­maceu­ti­cal company for single pills in the German market. The Company intends to use the net proceeds from the issu­ance of the new shares prima­rily for selec­ted invest­ments in the deve­lo­p­ment of new single pills, acce­le­ra­ting the deve­lo­p­ment and licen­sing of the exis­ting near-term product pipe­line, and expan­ding marke­ting and sales acti­vi­ties to capture addi­tio­nal market share and product acquisitions.

McDer­mott provi­ded compre­hen­sive capi­tal markets legal advice to all parties invol­ved. The McDer­mott team was also respon­si­ble for the corpo­rate struc­tu­ring in the run-up to the IPO.

Advi­sors APONTIS, Para­gon Part­ners and banks Hauck & Aufhäu­ser and M.M.Warburg:
McDer­mott Will & Emery, Frank­furt a.M./Düsseldorf
Capi­tal Markets/IPO Work­stream: Simon Weiß (Project Coor­di­na­tion; Capi­tal Markets), Joseph W. Marx (US Capi­tal Markets; joint lead), Gregory M. Weigand (Miami), Edwin C. Lauren­son (Coun­sel, San Fran­cisco; both US Law), Dr. Deniz Tschamm­ler (Munich), Dr. Monika Rich­ter (both Coun­sel, both Life Scien­ces); Asso­cia­tes: Dr. Marion von Grön­heim, Isabelle Suzanne Müller, Chris­toph Schä­fer, Ardalan Zargari (Staff Attor­ney); Corpo­rate Work­stream: Dr. Phil­ipp Gren­ze­bach (Lead), Dr. Thomas Gennert (both Corpo­rate, both Düssel­dorf); Asso­ciate: Tom Schäfer

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at] fyb.de